These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 11507208)

  • 1. Mechanisms involved in stimulation of human immunodeficiency virus type 1 replication by aminooxypentane RANTES.
    Marozsan AJ; Torre VS; Johnson M; Ball SC; Cross JV; Templeton DJ; Quiñones-Mateu ME; Offord RE; Arts EJ
    J Virol; 2001 Sep; 75(18):8624-38. PubMed ID: 11507208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs.
    Torre VS; Marozsan AJ; Albright JL; Collins KR; Hartley O; Offord RE; Quiñones-Mateu ME; Arts EJ
    J Virol; 2000 May; 74(10):4868-76. PubMed ID: 10775626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aminooxypentane-RANTES, an inhibitor of R5 human immunodeficiency virus type 1, increases the interferon gamma to interleukin 10 ratio without impairing cellular proliferation.
    Rusconi S; La Seta-Catamancio S; Kurtagic S; Galazzi M; Arienti D; Trabattoni D; Wilken J; Thompson DA; Offord RE; Galli M; Clerici M
    AIDS Res Hum Retroviruses; 1999 Jul; 15(10):861-7. PubMed ID: 10408722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity.
    Mack M; Luckow B; Nelson PJ; Cihak J; Simmons G; Clapham PR; Signoret N; Marsh M; Stangassinger M; Borlat F; Wells TN; Schlöndorff D; Proudfoot AE
    J Exp Med; 1998 Apr; 187(8):1215-24. PubMed ID: 9547333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes.
    Kawamura T; Bruse SE; Abraha A; Sugaya M; Hartley O; Offord RE; Arts EJ; Zimmerman PA; Blauvelt A
    J Virol; 2004 Jul; 78(14):7602-9. PubMed ID: 15220435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants.
    Mosier DE; Picchio GR; Gulizia RJ; Sabbe R; Poignard P; Picard L; Offord RE; Thompson DA; Wilken J
    J Virol; 1999 May; 73(5):3544-50. PubMed ID: 10196243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coreceptor usage and RANTES sensitivity of non-syncytium-inducing HIV-1 isolates obtained from patients with AIDS.
    Jansson M; Backström E; Björndal A; Holmberg V; Rossi P; Fenyö EM; Popovic M; Albert J; Wigzell H
    J Hum Virol; 1999; 2(6):325-38. PubMed ID: 10774549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
    Marozsan AJ; Kuhmann SE; Morgan T; Herrera C; Rivera-Troche E; Xu S; Baroudy BM; Strizki J; Moore JP
    Virology; 2005 Jul; 338(1):182-99. PubMed ID: 15935415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocytosis and recycling of the HIV coreceptor CCR5.
    Signoret N; Pelchen-Matthews A; Mack M; Proudfoot AE; Marsh M
    J Cell Biol; 2000 Dec; 151(6):1281-94. PubMed ID: 11121442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of CD3/CD28-mediated activation of the MEK/ERK signaling pathway represses replication of X4 but not R5 human immunodeficiency virus type 1 in peripheral blood CD4(+) T lymphocytes.
    Popik W; Pitha PM
    J Virol; 2000 Mar; 74(6):2558-66. PubMed ID: 10684270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The B-oligomer of pertussis toxin deactivates CC chemokine receptor 5 and blocks entry of M-tropic HIV-1 strains.
    Alfano M; Schmidtmayerova H; Amella CA; Pushkarsky T; Bukrinsky M
    J Exp Med; 1999 Sep; 190(5):597-605. PubMed ID: 10477545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of CCR5 and CXCR4 inhibitors in therapy of human immunodeficiency virus type 1 infection: in vitro studies of mixed virus infections.
    Rusconi S; La Seta Catamancio S; Citterio P; Bulgheroni E; Croce F; Herrmann SH; Offord RE; Galli M; Hirsch MS
    J Virol; 2000 Oct; 74(19):9328-32. PubMed ID: 10982382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells.
    Zhang Y; Lou B; Lal RB; Gettie A; Marx PA; Moore JP
    J Virol; 2000 Aug; 74(15):6893-910. PubMed ID: 10888629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of R5X4 dualtropic HIV-1 primary isolates by single chemokine co-receptor ligands.
    Ghezzi S; Menzo S; Brambilla A; Bordignon PP; Lorini AL; Clementi M; Poli G; Vicenzi E
    Virology; 2001 Feb; 280(2):253-61. PubMed ID: 11162839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of an unique CXCR4 epitope whose ligation inhibits infection by both CXCR4 and CCR5 tropic human immunodeficiency type-I viruses.
    Adachi T; Tanaka R; Kodama A; Saito M; Takahashi Y; Ansari AA; Tanaka Y
    Retrovirology; 2011 Oct; 8():84. PubMed ID: 22018245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.
    Trkola A; Ketas TJ; Nagashima KA; Zhao L; Cilliers T; Morris L; Moore JP; Maddon PJ; Olson WC
    J Virol; 2001 Jan; 75(2):579-88. PubMed ID: 11134270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages.
    Surdo M; Balestra E; Saccomandi P; Di Santo F; Montano M; Di Carlo D; Sarmati L; Aquaro S; Andreoni M; Svicher V; Perno CF; Ceccherini-Silberstein F
    PLoS One; 2013; 8(7):e68076. PubMed ID: 23874501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist.
    Simmons G; Clapham PR; Picard L; Offord RE; Rosenkilde MM; Schwartz TW; Buser R; Wells TN; Proudfoot AE
    Science; 1997 Apr; 276(5310):276-9. PubMed ID: 9092481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Galphai protein-dependant extracellular signal-regulated kinase-1/2 activation is required for HIV-1 reverse transcription.
    Mettling C; Desmetz C; Fiser AL; Réant B; Corbeau P; Lin YL
    AIDS; 2008 Aug; 22(13):1569-76. PubMed ID: 18670215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity.
    Baba M; Nishimura O; Kanzaki N; Okamoto M; Sawada H; Iizawa Y; Shiraishi M; Aramaki Y; Okonogi K; Ogawa Y; Meguro K; Fujino M
    Proc Natl Acad Sci U S A; 1999 May; 96(10):5698-703. PubMed ID: 10318947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.